Date
2021/4/6
2020/4/13
2020/4/20

Presenter
藤岡
宮﨑山田
佐藤
クリクラ
長井
渡辺

2020/4/27

澤山

古本加藤山田2020/5/18
長井
2020/5/11

クリクラ
2020/5/25
今泉
2020/6/1
2020/6/8
2020/6/15
2020/6/22
2020/6/29

勝岡
安東西村
宮﨑坂本
佐藤
クリクラ
長井
藤岡
澤山

Title
JournalYear Vol
Page
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
J Clin Oncol
2021 39(14)1584-1594
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells
Cell Stem Cell 2021 28(3)514-523
in Myeloproliferative Neoplasms
Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers
N Engl J Med
2021 384(10)924-935
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
N Engl J Med
2021 384(11)1028-1037
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: theBlood Adv
2021 5(4)984-993
JCOG0601 trial
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with largeNat
B cellMed
lymphomas2020 26(12)1878-1887
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic
J Clin Oncol
Syndromes
2021 39(13)1426-1436
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete
J Clin Oncol
2021
JCO2003175
Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously
Lancetuntreated,Oncol metastatic,
2020 21(3)non-squamous
387-397
non-small-cell lung cancer (KEYNLymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody
2020 180(5)878-894
Cell
日本リンパ網内系学会予行臨床研究説明「幹細胞輸注関連有害事象と移植合併症の相関の前向き観察研究」福島県立医科大学
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, UnfavorableJ Clin Oncol
2021
JCO2100108
Risk Hodgkin Lymphoma
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma:
J Clin Oncol
2021 39(15)1641-1649
Who Gets Left Behind?
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP
Blood Adv
2020 4(15)3586-3593
deliveryA hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation
Cancer Cell
2021 39(3)380-393
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP
Blood Adv
2021 5(8)2229-2236
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.
N Engl J Med
2020 383(27)2628-2638
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host DiseaseJ Clin Oncol
2021 39(17)1888-1898
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: AJ Clin Oncol
2021 39(14)1575-1583
Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
N Engl J Med
2021 384(22)2124-2130
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia
Blood Adv
2021 5(9)2350-2361
Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia
Nature2021 593(7860) 597-601
CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-toBlood Adv
2020 4(24)6157-6168
treat comparison